Acute renal failure and veno-occlusive disease of the liver are serious complications following stem cell transplantation (SCT) and contribute to the non-relapse mortality associated with this procedure. Endothelins, a family of vasoconstrictor peptides, may be involved in the pathogenesis of a variety of renal and hepatic diseases, including CsA-associated hypertension and the hepatorenal syndrome. In order to study the relevance of endothelins to SCT-related liver and kidney dysfunction, we determined endothelin-1 (ET-1) levels in plasma samples obtained from 65 patients (38 autologous, 27 allogeneic) 7 days before and 7, 14 and 28 days after SCT. A steady increase in plasma ET-1 was observed after SCT (5.36 pg/ml, 95% CI 4.30-6.43 on day +28 vs 3.82 pg/ml, 95% CI 3.21-4.43 on day −7; P = 0.020). No differences in ET-1 levels existed between autologous and allogeneic SCT recipients at any of the time points studied (P = 0.561). In addition, no significant differences were observed among patients with renal dysfunction vs those without (P = 0.187), nor in patient groups with or without hepatic dysfunction (P = 0.075). In conclusion, even though plasma ET-1 levels showed a steady increase following SCT, no correlation could be found with development of SCT-related kidney or liver dysfunction. Bone Marrow Transplantation (2000) 26, 1199-1204.
plications after allogeneic SCT. In particular, the use of CsA has been related to development of post-allogeneic SCT renal dysfunction and hypertension. 3, 4 Endothelin-1 (ET-1) is the main representative of a family of 21-amino-acid vasoconstrictor peptides. 5 It should be regarded as a paracrine hormone since it is secreted by endothelial cells and it can bind specific receptors on smooth muscle cells. 6 ET-1 exerts a wide range of biologic effects on the kidney, including constriction of most renal vessels, glomerular cell proliferation and contraction, inhibition of sodium and water reabsorption by the nephron, and modulation of blood pressure, plasma volume, and albumin escape. 7 Thus, deranged ET-1 production may be involved in the pathogenesis of a broad spectrum of renal diseases, including CsA-associated hypertension and nephrotoxicity. 8 ET-1 can also interact with receptors on the liver cell surface, 9, 10 causing vasoconstriction, constriction of hepatic sinusoids, and alteration in liver bile acid secretion. [11] [12] [13] In addition, as ET-1 increases hepatic portal vascular resistance, it has been hypothesized that it plays an important role in the pathogenesis of portal hypertension by increasing hepatic portal vascular resistance. 14 In general, the above evidence suggests the possibility that ET-1 may be involved in the pathogenesis of the hepatorenal syndrome associated with severe VOD.
The present study aimed to investigate whether patients treated with SCT exhibit elevated circulating plasma ET-1 concentrations and to determine whether this peptide may be relevant to the pathogenesis of SCT-related renal and hepatic dysfunction.
Materials and methods

Study subjects
Sixty-five patients who underwent transplantation from January 1994 to January 1995 were consecutively included in the study. Twenty-seven received an allogeneic SCT, while the remaining 38 underwent an autologous SCT with blood progenitors obtained either from bone marrow or peripheral blood (25 vs 13, respectively). Patient characteristics, diagnoses and pre-SCT preparative regimens are given in detail in Table 1 . All allogeneic SCT patients received CsA (Sandimmun; Novartis, Basel, Switzerland) from day −1 and methotrexate for the prevention of GVHD on days +1, +3, +6 and +11, as previously described. 15 A total of 11 healthy individuals were used as controls. Their liver and kidney function tests were within normal ranges and they did not suffer from any known liver or kidney dysfunction nor were they candidates for surgery. Bu = busulfan; Cy = cyclophosphamide; TBI = total body irradiation; TLI = total lymphoid irradiation; CBV = cyclophosphamide + BCNU + etoposide; Me = melphalan; BEAC = BCNU + etoposide + cytarabine + cyclophosphamide; CCT = cyclophosphamide + carboplatin + thiotepa.
Definitions
Acute renal failure was defined as when creatinine values had increased by at least twice their baseline values and also when levels higher than 2 mg/dl were reached. 1 Early transplant-related liver dysfunction was defined as when there was either an increase in alanine aminotransferase (ALT) levels above the normal value or when the bilirubin level was greater than 2 mg/dl. VOD was diagnosed according to clinical findings when the three major criteria (weight gain, jaundice and hepatomegaly) were present. 2, 16 Acute liver GVHD was classified according to Deeg and Storb's grading. 17 
Measurement of ET-1 plasma levels
Plasma samples were obtained from all patients 7 days before (prior to conditioning and initiation of CsA treatment -when appropriate) and 7, 14 and 28 days after SCT (Ϯ1 day). In patients treated with CsA, plasma samples were drawn immediately before administration of the morning dose of CsA. Samples were stored at −80°C and, at a later time, thawed, acidified with HCl, and centrifuged at 10 000 g for 5 min. The supernatants were purified by solid phase sorbent extraction using C2 ethyl columns (AmprepTM, Amersham, Buckinghamshire, UK), which had been previously activated with methanol and water, then washed with 0.1% trifluoroacetic acid (TFA) in water, and finally eluted with 0.1% TFA in 80% methanol. The eluted samples were dried in a centrifugal evaporator to be reconstituted in a buffer containing 0.9% NaCl, 0.1% BSA and 0.1% Tween-20. ET-1 concentrations in the reconstituted samples were measured with a commercial ELISA system (BioTrak, Amersham). Results were finally expressed in pg/ml. The mean recovery after extraction and ELISA measurement, determined by addition of known amounts of the peptide to control plasma samples, was 69.44 Ϯ 6.75% (mean Ϯ s.d.; n = 5).
Serum samples were collected in parallel from each patient at the same time points, to determine serum concentrations of creatinine, ALT, aspartate aminotransferase (AST), gamma-glutaryl transferase, alkaline phosphatase, and total and direct bilirubin.
Measurement of CsA levels
In those patients receiving an allogeneic SCT, CsA levels were routinely determined in whole blood samples collected into EDTA-containing tubes by fluorescence-polarization immunoassay (parent compound and metabolites; TDx system, Abbott, Chicago, IL, USA).
Statistical analysis
Results are given as mean and 95% confidence interval for the mean for the different time points studied within each group of patients or control subjects. Data within and between the different patient groups were compared using repeated measures ANOVA. One-way ANOVA was used to compare baseline pre-SCT ET-1 levels in patients undergoing either allogeneic or autologous SCT with ET-1 levels measured in control individuals. The Pearson's correlation coefficient was used to evaluate bivariate correlations between plasma ET-1 levels and serum concentrations of CsA, creatinine, and the different liver function parameters tested at each of the time points studied.
Results
SCT-related kidney and liver complications
The overall incidence of SCT-related acute renal failure was 13.8% (nine out of 65 patients), this being much lower than the 43.0% incidence found for hepatic dysfunction. Six patients (three allogeneic and three autologous SCT) developed VOD; the disease was severe in one case, moderate in three, and mild in two patients, according to McDonald's grading. 16 Seven out of 65 patients (10.8%) developed both acute renal failure and liver dysfunction. Interestingly, all seven patients had undergone an allogeneic SCT. As expected, acute renal failure and liver dysfunction were more common among those patients receiving an allogeneic SCT ( Table 2 ). The only exception to this trend was nonspecific liver toxicity (29.6% in allogeneic SCT patients vs 28.9% in autologous SCT patients). Overall, 53.8% of the patients did not develop liver or kidney dysfunction. Details of renal and hepatic function in allogeneic and autologous SCT patients at the given time points are shown in Table 3 .
Comparison of ET-1 levels between SCT patients and control subjects
No statistically significant difference was observed with regard to baseline plasma ET-1 concentrations between healthy control subjects and SCT patients before transplant (control subjects: 2.64 pg/ml, 95% CI 1.87-3.42; autologous SCT: 3.51 pg/ml, 95% CI 2.94-4.07; allogeneic SCT: 3.80 pg/ml, 95% CI 3.05-4.56; P = 0.176; Figure 1 ). However, as time went by, a steady increase in plasma ET-1 levels was observed in transplanted patients. Mean levels Given as median and range. Control Autologous Allogeneic CI 95% baseline ET-1 (pg/ml) Figure 1 Comparison of plasma ET-1 levels between control subjects, autologous and allogeneic SCT patients. Results are depicted as means with error bars indicating the upper and lower bounds of the 95% confidence interval for each mean. The different patient groups were compared with one-way ANOVA.
Bone Marrow Transplantation of ET-1 raised from 3.82 pg/ml on day −7 to 5.36 pg/ml on day +28 (P = 0.020; Figure 2) . As a whole, no differences in ET-1 levels were observed before and following transplantation between patients who received either autologous SCT or allogeneic SCT (P = 0,561; Figure 2 ).
Correlation between ET-1 levels and liver dysfunction
Plasma ET-1 levels were compared between patients who developed some type of hepatic dysfunction vs those who did not. Before SCT, no relationship could be found between baseline ET-1 levels and the development of post-SCT liver dysfunction (P = 0.781). Although not statistically significant (P = 0.075), a trend was observed for patients with liver dysfunction to demonstrate increased ET-1 concentrations with time after SCT. This was not modified by the type of SCT, either autologous or allogeneic (P = 0.560). Interestingly, ET-1 levels correlated well with transaminases ALT and AST serum concentrations on days +14 (r = 0.270, P = 0.045 and r = 0.249, P = 0.064, respectively) and +28 (r = 0.291, P = 0.050 and r = 0.384, P = 0.009, respectively). On the other hand, patients who did not experience any type of liver dysfunction, did not exhibit changes in plasma ET-1 levels with time after SCT (P = 0.179).
Patients who developed VOD did not show statistically significant differences in ET-1 concentrations when compared to other groups of patients. Yet, in three of the six patients who developed VOD the appearance of liver dysfunction paralled an increment in plasma ET-1 level. Moreover, plasma ET-1 concentrations were not apparently modified by the occurrence of acute renal failure or ascites in this subset of patients. On the other hand, two of the three patients who developed acute liver GVHD after an allogeneic SCT, experienced a progressive two-to threefold increase in plasma ET-1 levels. This change in ET-1 concentration coincided in time with the development of acute liver GVHD. No increase in ET-1 concentration with time was found in the third patient, who also developed acute renal failure. This different pattern did not seem to be related to the severity of GVHD, since this third patient developed acute liver GVHD grade +3 while the previous two patients had GVHD grades +2 and +3. It should be noted that there were no statistically significant differences in ET-1 levels at any of the time points studied between allogeneic SCT patients with or without any kind of acute GVHD, regardless of liver involvement (P = 0.146).
Correlation between ET-1 levels and kidney dysfunction
Again, no statistically significant differences in plasma ET-1 levels could be shown at any of the time points studied between patients who developed renal dysfunction vs those who did not (P = 0.187). In an attempt to study a potential relationship between renal function after SCT and ET-1 plasma levels, ET-1 concentrations were correlated with the serum creatinine concentration, but no significant association was found at any of the time points checked in patients who underwent either autologous or allogeneic SCT.
ET-1 plasma levels in CsA-treated patients
In this study, no change was found in plasma ET-1 concentrations during CsA treatment at any of the time points studied. Patients who received an allogeneic SCT and thus CsA as prophylaxis against GVHD, did not show elevated ET-1 levels compared to those individuals who received an autologous SCT and thus were not treated with CsA (P = 0.561; Figure 2 ). No statistically significant correlation was established at any of the time points studied for ET-1 plasma levels and CsA concentrations. Moreover, those patients with VOD, acute liver GVHD, and/or hepatorenal dysfunction did not have elevated CsA levels (data not shown).
Discussion
In the present study, we found an increment in plasma ET-1 concentration with time in patients undergoing SCT. This change in ET-1 concentration became evident and statistically significant 28 days after SCT, regardless of the transplant being autologous or allogeneic. Prior to SCT, there was no statistically significant rise in plasma ET-1 levels compared to the baseline levels of a control population. Elevated endothelin concentrations may only be a reflection of physiological phenomena common to all SCT patients, such as increased synthesis and/or release in the endothelium, endogenous synthesis in different organs (liver, kidney, etc), and decreased renal clearance. Cytokines 18 participating in immunological dysfunction during SCT and circulating toxins and endotoxins 19 may also play an essential role by stimulating production of endothelins.
Our interest in the potential involvement of ETs in the pathogenesis of the hepatorenal syndrome associated with severe VOD arose from several studies that demonstrated a role of ETs in portal hypertension 14 and hepatorenal syndrome-related functional renal failure. 20 In addition, the interaction of endogenous endothelins with specific receptors on the surface of hepatocytes 9,10 may be followed by constriction of hepatic sinusoids, 12 activation of glycogenolysis, 9 alteration in bile acid secretion, 11 and leakage of hepatocellular enzymes 21 from the liver. Surprisingly, patients who developed VOD as well as other types of liver dysfunction did not exhibit greater ET-1 concentrations than did other transplant patients without liver dysfunction. This finding raises serious doubts about the potential causative relationship between plasma endothelin levels and liver dysfunction resulting from VOD. Moreover, unlike the situation described by others, 22 we could not find a correlation between endothelin plasma levels and renal dysfunction in SCT recipients. Overall, our results do not exclude the possibility that endothelins may function as endogenous autocrine or paracrine factors within the kidney and the liver, thus contributing to the development of SCT-related hepatorenal syndrome. Furthermore, increased urinary endothelin excretion may be associated with renal dysfunction even when plasma endothelin concentrations are unchanged. 23 Unfortunately, in our study it was not possible to explore this possibility as urine samples from patients were not available.
High plasma endothelin concentrations have been previously reported in patients receiving an allogeneic SCT but not in those after autologous SCT. 3, 4 This phenomenon had been attributed to CsA treatment, as had been reported by other investigators of CsA-treated solid organ transplant recipients. 24 CsA enhances endothelin release from vascular endothelial cells, 25 smooth muscle cells, 26 and renal epithelial cells, 27 as well as upregulation of endothelin receptors. 28, 29 These actions of endothelins contribute to its ability to induce renal vasoconstriction, hypoperfusion, and decreased glomerular filtration, 7 which may in turn be reversed by endothelin inhibitors and antagonists. [30] [31] [32] However, in our studies as well as in those of others, [33] [34] [35] it was not possible to show a sustained rise in plasma endothelin levels in CsA-treated patients in comparison to nonCsA-treated individuals. This heterogeneity of observations may reflect that either peak levels or local tissue concentrations of CsA may be more relevant determinants of endothelin release than steady-state serum levels. Indeed, a recent study demonstrates that CsA may cause a time-dependent increase in ET-1 levels in both the liver and the kidney without an increase in the serum ET-1 level. 36 The elevated endothelin concentrations detected in allogeneic SCT recipients could also be the result of an immunemediated endothelialitis. A similar mechanism has been implicated in the pathogenesis of acute allograft rejection after solid organ transplantation; plasma endothelin concentrations would rise during acute rejection, and later subside to normal levels once rejection is overcome. 37, 38 This hypothetical mechanism could be particularly relevant to those patients who developed acute liver GVHD, in whom we were able to detect a two-to three-fold increment of plasma ET-1 levels.
In conclusion, we have shown that both autologous and allogeneic SCT are followed by a rise in ET-1 concentration. Even though endothelins are thought to be involved in mediating SCT-related liver and kidney dysfunction, in our study circulating plasma ET-1 levels showed no clear correlation as a predictive factor for the development of or with the development itself of any type of SCT-related kidney or liver dysfunction. Serial assessment of local endothelin levels in relevant organs in addition to plasma levels will probably be necessary to develop a better definition of the role of endothelins in the pathogenesis of these SCTrelated complications.
